Page 86 - Read Online

Page 128 De Mattia et al. Cancer Drug Resist 2019;2:116-30 I http://dx.doi.org/10.20517/cdr.2019.04

population-based cohort study of 4970 adults. PLoS One 2014;9:e92061.
5. Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, et al. The economic burden of common adverse events associated with
metastatic colorectal cancer treatment in the United States. J Med Econ 2017;20:54-62.
6. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
7. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med
2005;352:2696-704.
8. André T, Quinaux E, Louvet C, Colin P, Gamelin E, et al. Phase III study comparing a semimonthly with a monthly regimen of
fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin
Oncol 2007;25:3732-8.
9. Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Gomi K, et al. Analysis of neurosensory adverse events induced by FOLFOX4
treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Cancer Med 2012;1:198-206.
10. Chiara DF, Jerry P, Rossana R, Elena DM, Fabrizio E, et al. DPYD gene activity score (GAS) predicts dose-limiting toxicity in
fluoropyrimidine-treated colorectal cancer patients. JMCM 2018;1:143-50.
11. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:iii1-9.
12. Danesi R, Del Re M, Ciccolini J, Schellens JHM, Schwab M, et al. Prevention of fluoropyrimidine toxicity: do we still have to try our
patient’s luck? Ann Oncol 2017;28:183.
13. Deenen MJ, Meulendijks D. Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus
guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2017;28:184.
14. Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, et al. DPYD genotyping to predict adverse events following treatment with
flourouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized
clinical trial. JAMA Oncol 2016; doi: 10.1001/jamaoncol.2015.5392.
15. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer
treatment (NCCTG N0147). J Natl Cancer Inst 2014;106:dju298.
16. Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, et al. Clinical validity of a DPYD-based pharmacogenetic test to predict
severe toxicity to fluoropyrimidines. Int J Cancer 2015;137:2971-80.
17. Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, et al. Upfront Genotyping of DPYD*2A to individualize
fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 2016;34:227-34.
18. Henricks LM, Lunenburg CATC, Meulendijks D, Gelderblom H, Cats A, et al. Translating DPYD genotype into DPD phenotype: using
the DPYD gene activity score. Pharmacogenomics 2015;16:1277-86.
19. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, et al. Clinical pharmacogenetics implementation consortium
(CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther
2018;103:210-6.
20. Lunenburg CATC, Henricks LM, Dreussi E, Peters FP, Fiocco M, et al. Standard fluoropyrimidine dosages in chemoradiation therapy
result in an increased risk of severe toxicity in DPYD variant allele carriers. Eur J Cancer 2018;104:210-8.
21. Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/
HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of
individual patient data. Lancet Oncol 2015;16:1639-50.
22. Lunenburg CA, van Staveren MC, Gelderblom H, Guchelaar HJ, Swen JJ. Evaluation of clinical implementation of prospective DPYD
genotyping in 5-fluorouracil- or capecitabine-treated patients. Pharmacogenomics 2016;17:721-9.
23. Innocenti F. DPYD variants to predict 5-FU toxicity: the ultimate proof. J Natl Cancer Inst 2014;106:dju351.
24. Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, et al. Cost evaluation of irinotecan-related toxicities associated with the
UGT1A1*28 patient genotype. Clin Pharmacol Ther 2017;102:123-30.
25. Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, et al. The genotype for DPYD risk variants in colorectal cancer patients and the
related toxicity management costs in clinical practice. Clin Pharmacol Ther 2018; doi: 10.1002/cpt.1257.
26. Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, et al. A cost analysis of upfront DPYD genotype-guided
dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer 2019;107:60-7.
27. Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, et al. Preemptive pharmacogenetic testing: exploring the knowledge
and perspectives of US payers. Genet Med. 2017; doi: 10.1038/gim.2017.181.
28. Cecchin E, Roncato R, Guchelaar HJ, Toffoli G; Ubiquitous Pharmacogenomics Consortium. Ubiquitous pharmacogenomics (U-PGx):
the time for implementation is now. An Horizon2020 Program to drive pharmacogenomics into clinical practice. Curr Pharm Biotechnol
2017;18:204-9.
29. van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, et al. Implementing pharmacogenomics in
Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther 2017;101:341-58.
30. Duthie SJ. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis
2011;34:101-9.
31. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy
personalisation. Eur J Cancer 2009;45:1333-51.
32. Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, et al. Methylenetetrahydrofolate reductase genotype in diffuse large B-cell
lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. Int J Biol Markers